| Similar Articles |
|---|
 |
The Motley Fool
April 30, 2007
Brian Lawler |
Nothing Wrong With Endo Endo Pharmaceuticals releases first-quarter financial results. Investors, take note.   |
The Motley Fool
February 26, 2007
Brian Lawler |
Endo Brings in the Dough Why buy this pharmaceutical? Investors, let me count the ways. |
Chemistry World
May 26, 2015
Phillip Broadwith |
Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt. |
The Motley Fool
August 1, 2007
Brian Lawler |
Calling Out Endo Endo Pharmaceuticals gets taken to task by an activist investor. An investment group owning 5.6% of outstanding shares is concerned with how management plans to use $700 million available to them in cash and investments. |
The Motley Fool
September 29, 2010
Brian Orelli |
A Mini-Teva in the Making Generic growth by Endo Pharmaceuticals. |
The Motley Fool
August 3, 2007
Brian Lawler |
Endo Adjusting to Bigger Hopes The pharma announces its second-quarter financial results. As worries recede about near-term generic competition for lead drug Lidoderm, expectations for Endo have grown. |
The Motley Fool
January 30, 2008
Brian Lawler |
The Endo a CEO Shares of Endo Pharmaceutical rise after its CEO, Peter Lankau, resigns. |
The Motley Fool
November 6, 2007
Brian Lawler |
The Two Sides of Endo It has been a mixed third quarter for Endo Pharmaceuticals. On the financial side of things the company performed well; on the research and development side, things are not as good. |
The Motley Fool
December 30, 2010
Brian Orelli |
That's What You Call Product Differentiation? Endo Pharma misses the mark with its treatment for low testosterone, which the Food and Drug Administration approved yesterday. |
The Motley Fool
January 22, 2007
Brian Lawler |
The Feds Eye Endo Endo Pharmaceuticals' sales practices for Lidoderm prompt government scrutiny. Investors don't seem too concerned. |
The Motley Fool
January 10, 2007
Brian Lawler |
Endo's Plan to Bring In the Dough Despite little movement in the value of their shares, 2006 was an eventful year for investors in drug developer Endo Pharmaceuticals. |
The Motley Fool
October 23, 2006
Brian Lawler |
Not the End for Endo An FDA decision won't hurt the maker of Lidoderm. Investors, take note. |
The Motley Fool
February 25, 2008
Brian Lawler |
The Yin and Yang of Endo Endo Pharmaceuticals' fiscal 2007 report offered positive year-end financial results and a little bit of balance-sheet sourness. |
The Motley Fool
April 30, 2008
Brian Lawler |
The Start of a New Endo The drugmaker marks its first quarter under new management. |
The Motley Fool
April 30, 2007
Brian Orelli |
No Pain for Endo's Investors Endo Pharmaceuticals had an impressive first quarter thanks to a new product and continued sales growth of its older brands. Investors, take note. |
Chemistry World
March 25, 2015
Phillip Broadwith |
Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals. |
Chemistry World
October 10, 2014
Phillip Broadwith |
Endo outbids QLT for Auxilium merger US biotech Auxilium has backed out of a merger with Canadian firm QLT, in favor of a deal with US-based Endo. |
The Motley Fool
January 19, 2007
Brian Lawler |
The Best Drug Stock for 2007: Endo Pharmaceuticals This drug-maker just might be a great investment at the current price. |
The Motley Fool
March 20, 2007
Brian Lawler |
A Slowdown at Endo The FDA delays a decision on expanding the label for one of Endo's drugs. Investors, take note. |
The Motley Fool
October 3, 2007
Brian Lawler |
FDA Says Nay to Endo Endo Pharmaceuticals announces that the FDA issued a "not approvable" letter in response to the company's attempt to expand the label for migraine treatment Frova. |
BusinessWeek
December 11, 2006
Michael Arndt |
When A Winner Starts To Wane Endo is seeking to immunize itself from the slowing growth of its Lidoderm pain patch. |
The Motley Fool
April 1, 2008
Brian Lawler |
The Endo a Patent? Endo sues to protect a lead drug from generic competition. |
The Motley Fool
June 11, 2007
Brian Lawler |
Endo Shows Frova Endo releases more clinical trial results for one of its compounds. It's clear that the pharma will need new indications for which to market Frova if it wants to generate substantial new sales growth for the drug. Investors, take note. |
Chemistry World
September 2, 2013
Emma Stoye |
Endo Health to buy Boca Pharmacal for $225m US speciality healthcare company Endo Health Solutions has agreed to buy Boca Pharmacal for $225 million in a bid to expand its generics business. |
The Motley Fool
December 28, 2007
Brian Lawler |
Endo and Alexza Team Up Endo Pharmaceuticals and Alexza Pharmaceuticals announce a collaboration deal for an early-stage Alexza drug. |
Bio-IT World
August 18, 2004
Anthony Strattner |
The Pursuit of Process Endo Pharmaceuticals made the strategic decision to enter the electronic age of regulatory submissions, though enduring the demands of automating this core business process was eye-opening. |
The Motley Fool
August 18, 2010
Travers & Jayson |
Will Endo Pharmaceuticals Holdings Burn You? Endo Pharmaceuticals Holdings is cash flow-positive, and has been for quite some time. That's investment nirvana for biotech shareholders. |
The Motley Fool
September 22, 2010
Seth Jayson |
Will Endo Pharmaceuticals Holdings Whiff on Revenues Next Quarter? Is Endo Pharmaceuticals sending any warning signs? Take a look at its accounts receivable and days sales outstanding for a clue. |
Chemistry World
June 7, 2013
Phillip Broadwith |
Job cuts at three US pharma companies Endo will shed 15% of its global workforce by mid 2014; Impax is cutting 110 manufacturing and sales positions (around 12% of its workforce); and Zogenix is laying off 55 of its 148 staff (37%). |
The Motley Fool
June 13, 2007
Billy Fisher |
The Best Drug Stock for 2007 Revisited With half of the season left, anything can happen and no lead is safe -- especially in the biotech/pharmaceutical industry. For now the leader, Endo Pharmaceutical, is head and shoulders above the rest. |
The Motley Fool
January 11, 2011
Seth Jayson |
Here's How Endo Pharmaceuticals Is Making You So Much Cash With questionable cash flows actually reducing operating cash flow slightly, Endo Pharmaceuticals' cash flows look clean. |
